TACSTD2 and triple-negative breast carcinoma: Recently, the first anti-TROP2 ADC, sacituzumab govitecan, which is a humanized IgG1 conjugated to irinotecan metabolite (SN-38), has been approved by the US Food and Drug Administration against metastatic triple-negative breast cancers (23).